Novo Nordisk's Diabetes and Obesity Drugs Boost Net Profit
May 03 2019 - 3:03AM
Dow Jones News
By Dominic Chopping
Danish pharmaceutical company Novo Nordisk AS (NOVO-B.KO) on
Friday posted forecast-beating first-quarter net profit on the
strength of its diabetes and obesity treatments, but the negative
effects of foreign-exchange hedges weighed on the result.
Net profit for the three months ended March 31 fell to 10.45
billion Danish kroner ($1.57 billion) from DKK10.75 billion a year
earlier, beating the DKK9.74 billion forecast by analysts in a
FactSet poll. Sales rose 8.8% to DKK29.29 billion against analysts'
expectations of DKK28.93 billion.
"We delivered very solid performance in international
operations, driven by sales growth in all regions, meanwhile, sales
in the U.S. were negatively impacted by inventory reductions," said
Chief Executive Lars Fruergaard Jorgensen.
Sales in the quarter were boosted by Novo Nordisk's diabetes and
obesity treatments, but margins came under pressure due to lower
margin insulin products and lower prices, primarily related to the
insulin market in the U.S.
The company reiterated intensifying global competition both
within diabetes and biopharmaceuticals, especially within the
hemophilia-inhibitor segment.
In addition, continued pricing pressure within diabetes is
expected, especially in the U.S.
Foreign-exchange losses totaled DKK876 million in the quarter
compared with a gain of DKK1.11 billion last year.
"This development reflects a loss on foreign-exchange hedging,
involving especially the U.S. dollar versus the Danish krone," the
company said.
For 2019, sales growth measured in local currencies is still
seen at 2% to 5%, but reported growth is now expected to be around
three percentage points higher, from a previous expectation of
around two percentage points higher.
Operating profit growth is still expected to be 2% to 6%
measured in local currencies, while reported figures are now
expected to be around five percentage points higher from previous
guidance of around 4 percentage points higher.
However, the company said it now sees a loss of around DKK3.3
billion under financial items this year, due to foreign-exchange
hedging losses. It previously saw a loss of around DKK2.4
billion.
Write to Dominic Chopping at dominic.chopping@wsj.com;
@domchopping @WSJNordics
(END) Dow Jones Newswires
May 03, 2019 02:48 ET (06:48 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024